Evidence map›GLP-1 receptor agonists × cardiac & vascular function›PMID 27790809›Full record

Trial reportEuropean journal of heart failure2017

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.

Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen and 7 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of heart failure, 2017. The graph read 2 numbers from its abstract, feeding 2 cells of the map: it finds no clear difference in 1. It is linked to trial NCT06455878 (The Impact of Dietary Management Applet for Weight Reduction in Obese Heart Failure Patients), which is not on this map. Cited by 260 papers, 14 of them syntheses that pooled it.

2numbers the graph read from it
1cell of the map it votes in
260citing papers in PubMed, 14 pooled it
31.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
-2.100.500 · no effect
Change in LVEFliraglutide 1.8 mg once daily vs matching placebono clear difference · ascvd, arrhythmiafeeds one cell of the map
Δ -0.80-2.10 to 0.500.24
Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24).
FeedsGLP-1 receptor agonists×cardiac & vascular function

Read, but not usablea number the graph found but could not read as for or against

Heart rateliraglutide 1.8 mg once daily vs matching placebodirection of benefit for this outcome is not defined · ascvd, arrhythmiafeeds one cell of the map
Δ 7.005.00 to 9.00<0.0001
Heart rate increased with liraglutide [mean difference: 7 b.p.m.
FeedsGLP-1 receptor agonists×adverse events & safety

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×cardiac & vascular function

InconclusiveOpen on the map →What to test next →

6 readable studies in this cell: 3 favour the treatment, 2 find no difference, 1 favour the comparator.

Belief with this paper
0.50contested · 3 families support, 1 contradict · against placebo
Without it
0.50This paper does not move the number.
← favours the comparatorfavours the treatment →
0 · no effect
This paper · 2017
Δ -0.80-2.10 to 0.50
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 …PMID 38587233 · 617 enrolled · 2021
change 0.670.55 to 0.80
NCT04788511529 enrolled · 2021
Δ 7.804.80 to 10.9
NCT0488111060 enrolled · 2021
Δ 25.121.8 to 28.3
Effect of liraglutide on cardiac function in patients with type 2 diab…PMID 31039778 · 50 enrolled · 2013
Δ 1.00
Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the …PMID 38819334 · 2024
Δ 4.500.80 to 8.20

GLP-1 receptor agonists×adverse events & safety

No readable resultOpen on the map →What to test next →

40 readable studies in this cell: 47 favour the treatment, 14 find no difference, 2 favour the comparator.

Belief with this paper
0.02contested · 1 family supports, 41 contradict · against placebo
Without itNot a counted family in this claim, so removing it changes nothing.
← favours the treatmentfavours the comparator →
0 · no effect
NCT017204463,297 enrolled · 2013
Δ -0.66-0.80 to -0.52
NCT036893742,274 enrolled · 2018
Δ -0.29-0.38 to -0.20
NCT013360231,663 enrolled · 2011
Treatment contrast -0.64-0.75 to -0.53
NCT040178321,441 enrolled · 2019
Δ -0.20-0.30 to -0.10
NCT018365231,398 enrolled · 2013
Δ -0.20-0.32 to -0.07
NCT019301881,231 enrolled · 2013
Δ -1.06-1.21 to -0.91
NCT007344741,202 enrolled · 2008
Δ -0.71-0.87 to -0.55
NCT008389031,049 enrolled · 2009
Δ -0.91-1.16 to -0.65
NCT009606611,036 enrolled · 2009
Δ -0.04-0.18 to 0.11
NCT050350821,018 enrolled · 2021
Δ -0.24-0.44 to -0.04
NCT01064687978 enrolled · 2010
Δ -1.05-1.22 to -0.88
NCT01117350978 enrolled · 2010
Δ 2.54-3.88 to 8.93

This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.

4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06455878 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Impact of Dietary Management Applet for Weight Reduction in Obese Heart Failure Patients: a Multicenter, Single-blind Randomized Controlled Trial

TypeinterventionalSponsorHeart Health Research CenterRan2024 to 2026Enrolled830ConditionsHeart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection FractionArmsFull usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scale
5 · Its place in the literature

Who cites it

260 citing papers in PubMed, 14 syntheses or guidelines pooled it, 533 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  20. Review

200 more citing papers are in PubMed but not listed here.

6 · The record

Corrections and comments

7 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Anders JorsalDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Caroline KistorpDepartment of Endocrinology and Internal Medicine, Herlev University Hospital, Copenhagen, Denmark.
Pernille HolmagerDepartment of Endocrinology and Internal Medicine, Herlev University Hospital, Copenhagen, Denmark.
Rasmus Stilling TougaardDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Roni NielsenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Anja HänselmannDepartment of Cardiology, Odense University Hospital, Odense, Denmark.
Brian NilssonDepartment of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
Jacob Eifer MøllerDepartment of Cardiology, Odense University Hospital, Odense, Denmark.
Jakob HjortDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Jon RasmussenDepartment of Endocrinology and Internal Medicine, Herlev University Hospital, Copenhagen, Denmark.
Trine Welløv BoesgaardSteno Diabetes Center, Gentofte, Denmark.
Morten SchouFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Lars VidebaekDepartment of Cardiology, Odense University Hospital, Odense, Denmark.
Ida GustafssonDepartment of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
Allan FlyvbjergDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Henrik WiggersDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Lise TarnowSteno Diabetes Center, Gentofte, Denmark.
Aarhus University · DKOdense University Hospital · DKAarhus University Hospital · DKHvidovre Hospital · DKUniversity of Copenhagen · DKGentofte Hospital · DKHerlev Hospital · DKSteno Diabetes Center · DK

Funding

No grant is acknowledged in the PubMed record.

8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

aimsTo determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. METHODS AND

resultsLIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

conclusionLiraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Indexed as

Stroke VolumeVentricular Function, LeftAcute Coronary SyndromeAgedAtrial FibrillationChronic DiseaseDiabetes Mellitus, Type 2Disease ProgressionDouble-Blind MethodEchocardiographyFemaleHeart FailureHeart RateHumansIncretinsLiraglutideIncretinsLiraglutideNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Glucagon-like peptide-1Heart failureHeart rateLeft ventricular functionLiraglutideType 2 diabetes

Identifiers

PMID27790809
OpenAlexW2542456927

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.